The American College of Rheumatology’s (ACR) The Lupus Initiative (TLI) has awarded a one-year, $500,000 grant from the Office of Minority Health (OMH) to expand its established, national education program with development of an evidence-based program model aimed at improved health outcomes for people with lupus living…
News
Janus Biotherapeutics (Janus), a Boston, Massachusetts based autoimmunity therapeutics company dedicated to development of novel, orally available compounds for treating autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjogren’s syndrome, psoriasis, and scleroderma, have announced their entry into a collaboration with multinational pharma firm Roche…
XTL Biopharmaceuticals Ltd., a biopharmaceutical company focused on the acquisition, development, and commercialization of pharmaceutical products for the treatment of unmet clinical needs, recently announced the results of a Phase 2b study on the efficacy and safety of its investigational drug candidate, hCDR1 (Edratide) for the treatment of systemic lupus…
Results from a study recently published in the journal Arthritis Care and Research showed that the lower extremity strength or weakness of women with systemic lupus erythematosus (SLE) was predictive of later higher or lower functional status but was unrelated to grip strength. Evidence showed that reduced…
Optimizing clinical care for patients with systemic lupus erythematosus (SLE) starts with understanding how disease activity affects health-related quality of life. Unless patients are able to report on their feelings and symptoms, clinicians are unable to determine how best to help their patients. Further, unless researchers determine how patients’ symptoms…
In a new study entitled “Treatment of systemic lupus erythematosus patients with the BAFF antagonist “peptibody” blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials” authors determined the safety, tolerability and efficacy of blisibimod, a B cell-activating factor antagonist, in patients with systemic…
Osteoporosis, a disease of low bone mass, can occur secondary to diseases such as systemic lupus erythematosus (SLE). While SLE itself does not seem to cause osteoporosis, chronic inflammation and long-term treatment with glucocorticoids can play a major role in inducing osteoporosis. In particular, it was shown in the article,…
A Phase 2 clinical trial testing the safety and efficacy of hCDR1 (Edratide) in patients with systemic lupus erythematosus (SLE) met its secondary endpoint, but not its first endpoint, suggesting that SLE patients may benefit from treatment. However, additional studies are required to be definitive. “A…
While biomedical research and development has come a long way in understanding lupus and how to manage it, experts believe they have barely made a dent in this autoimmune disease’s complexity and elusiveness. Many diseases stem from and degrade specific organs, which leads to tell-tale symptoms. Lupus, however, tends to…
Australian pharmaceutical giant Invion Limited, recently completed its phase II clinical study on INV103 (ala-Cpn10) in patients with systemic lupus erythematosus (SLE). The study was designed to test the biochemical properties of the drug in escalating doses, administered to patients with SLE and other autoimmune disorders, in considerably higher numbers…
Recent Posts
- Understanding the grief of chronic illness has made me more self-aware
- Sometimes you just have to sit in the mess of lupus for a while
- Twin Phase 3 studies recruiting adults with lupus skin problems in US, Canada
- Understanding how menopause can affect our lupus symptoms
- Discovering a role the vagus nerve plays in chronic pain management